Estimates of prevalence have considerable variation due to differences in analytical and surveying approach, and the choice of diagnostic criteria. An estimated 384 million people had<unk>  in 2010, corresponding to a global prevalence of 12%. The disease affects men and women. The increase in the developing world between 1970 and the 2000s is believed to be related to increasing rates of smoking in this region, an increasing population and an aging population due to fewer deaths from other causes such as infectious diseases. Some developed countries have seen increased rates, some have remained stable and some have seen a decrease in<unk>  prevalence. Around three million people die of<unk>  each year. In some countries, mortality has decreased in men but increased in women. This is most likely due to rates of smoking in women and men becoming more similar. A higher rate of<unk>  is found in those over 40 years and this increases greatly with advancing age with the highest rate found in those over 60 years. In the UK three million people are reported to be affected by<unk> two million of these being undiagnosed. On average the number of<unk> -related deaths between 2007 and 2016 was 28,600. The estimated number of deaths due to occupational exposure was estimated to be about 15% at around 4,000. In the United States in 2018 almost 15.7 million people had been diagnosed with<unk> , and it is estimated that millions more have not been diagnosed. In 2011, there were approximately 730,000 hospitalizations in the United States for<unk> . Globally<unk>  in 2019 was the third leading cause of death. In low-income countries<unk>  does not appear in the top 10 causes of death; in other income groups it is in the top 5.
Chronic obstructive pulmonary disease
Tracheobronchomalacia
Asthma
Bronchiectasis
Reactive airway disease
Pneumonia
End stage pulmonary disease
Acute bronchitis